NEW YORK, Nov 3 (Reuters) - Biogen Idec Inc (BIIB.O) plans to cut 13 percent of it workforce, consolidate research sites and halt some drug development under a broad effort to cut costs.
NEW YORK, Nov 3 (Reuters) - Biogen Idec Inc (BIIB.O) plans to cut 13 percent of it workforce, consolidate research sites and halt some drug development under a broad effort to cut costs.
